Pay in 4 interest-free payments of $7.26 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
The differences observed can be attributed to several factors inherent to real-world studies as compared to RCTs, and future work is needed to further characterize patient profiles most likely to benefit from GLP-1s with findings from both structured and unstructured clinical data modalities
doi: 10.3389/fimmu.2022.1089987 137 ZouJReddivariLShiZLiSWangYBretinAet al
It has been established through clinical trials that GLP-1 receptor agonists (liraglutide and semaglutide) have proven to be consistently useful in lowering body weight, enhancing glycaemic control, and reducing cardiovascular risk [7,8,9].Nevertheless, since GLP-1 receptor agonists have the capability to work on several central nervous pathways, including the one controlling appetite, reward circuits, and the pancreatic-enteric-brain axis, the potential psychological impact of such agonists has increased with time [10,11,12]
Here, Norris, a physician assistant, explains what you need to know about GLP-1s and how they complement weight loss surgery
The trials showed meaningful weight loss at every dose level
Ueda P, Soderling J, Wintzell V, Svanstrom H, Pazzagli L, Eliasson B, et al
